Pharmaceutical composition for treating cardiovascular diseases and preparation method and use thereof

A composition and cardiovascular technology, applied in the direction of cardiovascular system diseases, drug combinations, pharmaceutical formulas, etc., can solve undiscovered problems, reduce adverse reactions, improve antihypertensive effect, and reduce the number of times of taking

Inactive Publication Date: 2010-04-07
GUANGXI FANGLUE GROUP LONGZHOU PHARMA
View PDF51 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, no patent literature or other literature reports on the pharmaceutical composition composed of eprosartan, amlodipine and hydrochlorothiazide have been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating cardiovascular diseases and preparation method and use thereof
  • Pharmaceutical composition for treating cardiovascular diseases and preparation method and use thereof
  • Pharmaceutical composition for treating cardiovascular diseases and preparation method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] Embodiment 1 eprosartan amlodipine hydrochlorothiazide film-coated tablet (300 / 5 / 25mg)

[0085] prescription:

[0086] Component Dosage

[0087] Amlodipine 5.0g

[0088] Hydrochlorothiazide 25.0g

[0089] Eprosartan 300.0g

[0090] Microcrystalline Cellulose 150.0g

[0091] Lactose 60.0g

[0092] Povidone 25.0g

[0093] Magnesium Stearate 5.0g

[0094] Opadry Appropriate amount

[0095] 5% starch slurry appropriate amount

[0096] A total of 1000 pieces were made

[0097] Preparation:

[0098] Pass the above prescription amount of the principal ingredient and auxiliary materials through an 80-mesh sieve, and then mix the prescription amount of amlodipine, hydrochlorothiazide, and eprosartan evenly by equal-volume incremental method. Then mix the well-mixed main ingredient with other auxiliary materials and 70% povidone evenly, make soft material with prepared 5% starch slurry, pass through 18 mesh sieve and granulate, dry at 60°C for 3 hours, and use 22 mesh ...

Embodiment 2

[0100] Embodiment 2 eprosartan amlodipine hydrochlorothiazide film-coated tablet (400 / 5 / 25mg)

[0101] prescription:

[0102] Component Dosage

[0103] Amlodipine 5.0g

[0104] Hydrochlorothiazide 25.0g

[0105] Eprosartan 400.0g

[0106] Microcrystalline Cellulose 200.0g

[0107] Lactose 80.0g

[0108] Sodium carboxymethyl starch 40.0g

[0109] Magnesium Stearate 8.0g

[0110] Opadry Appropriate amount

[0111] 5% starch slurry appropriate amount

[0112] A total of 1000 pieces were made

[0113] Preparation:

[0114] Pass the above prescription amount of the principal ingredient and auxiliary materials through an 80-mesh sieve respectively, and then mix the prescription amount of amlodipine and hydrochlorothiazide eprosartan evenly by the method of equal addition. Then the well-mixed main ingredient is mixed evenly with other auxiliary materials and 70% carboxymethyl starch sodium, and the soft material is made of 5% starch slurry prepared, granulated through a 18...

Embodiment 3

[0116] Embodiment 3 eprosartan amlodipine hydrochlorothiazide film-coated tablet (600 / 5 / 12.5mg)

[0117] prescription:

[0118] Component Dosage

[0119] Amlodipine 5.0g

[0120] Hydrochlorothiazide 12.5g

[0121]Eprosartan 600.0g

[0122] Microcrystalline Cellulose 200.0g

[0123] Pregelatinized starch 120.0g

[0124] Povidone 40.0g

[0125] Magnesium Stearate 8.0g

[0126] Opadry Appropriate amount

[0127] 5% PVP-K30 appropriate amount

[0128] A total of 1000 pieces were made

[0129] Preparation:

[0130] Pass the above prescription amount of the principal ingredient and auxiliary materials through an 80-mesh sieve, and then mix the prescription amount of amlodipine, hydrochlorothiazide, and eprosartan evenly by equal-volume incremental method. Then the well-mixed main ingredient is mixed evenly with other auxiliary materials and 70% povidone, and the prepared soft material is made of 5% PVP-K30, granulated through a 18-mesh sieve, dried at 60°C for 3 hours, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition containing eprosartan, amlodipine and hydrochlorothiazide and a prepration method and a use thereof, the composition consists of the eprosartan, the amlodipine and the hydrochlorothiazide, and the composition is used for treating patients with moderate hypertension, severe hypertension, coronary heart disease and angina and the patients with the hypertension, the coronary heart disease and the angina, wherein blood pressure of the patients can not be fully controlled after using an angiotensin II receptor antagonist or a calcium antagonist for treating.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating cardiovascular disease and a preparation method thereof, in particular to the pharmaceutical composition prepared with eprosartan, the calcium antagonist amlodipine and the diuretic hydrochlorothiazide and its application. Background technique [0002] Eprosartan is an angiotensin II receptor antagonist, and its mesylate is mainly used clinically. Its chemical name is: 4-[[2-butyl-5-(2-formyl-3-thiophen-2-yl-propen-1-yl)-imidazol-1-yl]methyl]benzoic acid methanesulfonate acid salt, its molecular formula is: C 23 h 24 N 2 o 4 SCH 4 o 3 S, its molecular weight is: 520.62, and its structural formula is: [0003] [0004] Eprosartan was first launched in Germany in 1998. In the United States, eprosartan is the fastest-growing type of hypertension in the market, with annual sales of about 2.6 billion U.S. dollars and an annual growth rate of 34%. Eprosartan is an angiotensin II r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/549A61K31/4178A61K31/4422A61P9/00A61P9/12A61P9/10
Inventor 杨进明王德武莫国飞
Owner GUANGXI FANGLUE GROUP LONGZHOU PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap